| Cardiovascular – MO opportunities |
Prescribing Data Report |
March 2026 |
| Cardiovascular System |
Prescribing Data Report |
February 2026 |
| Formulary assessment – Spironolactone (Qaialdo) 10 mg/1 ml oral suspension |
Formulary assessment tools |
July 2025 |
| Comparison of DOACs for Atrial Fibrillation |
Prescriber Support Tools |
June 2025 |
| Formulary assessment – Flecainide Acetate 25mg/5mL Oral Solution (Colonis) |
Formulary assessment tools |
April 2025 |
| NHS Medicines Optimisation Opportunities Dashboard |
Prescribing Data Report |
May 2025 |
| Atrial Fibrillation [NICE NG196]: Financial and commissioning impact |
Prescribing bulletin |
August 2021 |
| Cardiovascular outcomes associated with SGLT2 inhibitors (update 2) |
Medicines in Practice |
December 2020 |
| Cardiovascular outcomes associated with GLP1 receptor agonists (updated) |
Medicines in Practice |
November 2020 |
